Blanda Stammen

Blanda is a highly motivated Drug Discovery Scientist and Research Project Leader with more than 30 years experience in Pharmaceutical R&D, with a proven ability to deliver drug candidates and to build, manage & lead matrix teams. She is a co-inventor of Maraviroc (Celsentri/Selzentry). Blanda has in-depth Medicinal Chemistry design experience across a number of small molecule projects in various therapeutic areas from early discovery through to Proof-of-Concept. She has always been driven by the passion to make a difference to patients’ lives.

As Medicinal Chemist she worked in multiple therapeutic areas, e.g. Antivirals, Antifungals and Pain, across various gene families like GPCRs, enzymes and ion channels. She was the Senior Medicinal Chemist of a team assigned with the design and identification of the first marketed CCR5 inhibitor maraviroc (Celsentri/Selzentry) for the treatment of HIV for which she received the ACS Heroes of Chemistry Award. Whilst working on treatments for pain she was the leading contributor of a global team (Japan), responsible for the design and identification of a first-in-class sodium channel inhibitor. During her time as a Medicinal Chemist she directly supervised synthetic chemistry teams with varying levels of individual experience and performance, providing performance evaluation, tailored technical coaching and work plans.

Blanda graduated from the Ruhr University in Bochum, Germany. She obtained her PhD (Dr. rer. nat.) after only two years of research with Professors P Welzel and W. Roth, for which she was awarded a student prize from the Deutsche Forschungsgemeinschaft, the leading science funding body in Germany. After 18 months of post-doctoral research with Prof. W. Oppolzer in Geneva, Switzerland, she joined Pfizer in 1993.

Blanda is author or co-author on more than 30 patents and publications.

Expertise
, , , , , ,

back to teams